<DOC>
	<DOCNO>NCT00284336</DOCNO>
	<brief_summary>This open label Phase II study elderly patient ( 65y old ) early breast cancer candidate adjuvant chemotherapy . A scheme liposomal doxorubicin ( Caelyx ) cyclophosphamide ( endoxan ) use . The aim study cardiac effect liposomal doxorubicin new non-invasive technique , ie strain rate imaging , classical echocardiography , special blood test measure troponin I BNP .</brief_summary>
	<brief_title>Caelyx Adjuvant Elderly Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically proven early breast cancer require adjuvant chemotherapy accord treat physician ( lymph node positive feature high risk accord StGallen criterion ) . Age &gt; 65 year Normal cardiac function ( assessment LVEF MUGA scan echocardiography lower limit normal institution ) . Performance status 0 2 ( WHO scale ) The determination ER PgR mandatory ( immunohistochemical method require ; ER and/or PgR positivity define &gt; 1 % positive cell ) . Also determination Her2neu mandatory , either immunohistochemistry FISH Adequate organ function ( define neutrophils &gt; 1.5 x109/L , Platelets &gt; 100 x 109/L , Hemoglobin &gt; 10 g/dl , total bilirubin &gt; 1.5 UNL , ASAT ( SGOT ) ALAT ( SGPT ) &gt; 1.5 UNL , alkaline phosphatase &gt; 2.5 UNL , creatinine &gt; 1.5 mg/dl ( 150 Âµmol/L ) Complete stag workup within 2 month prior registration . All patient bilateral mammography , chest Xray ( PA lateral ) and/or CTscan , abdominal ultrasound and/or CT scan , bone scan . In case positive bone scan suspicious metastasis , bone Xray ( bone CTscan spinal hot spot ) mandatory rule possibility metastatic disease . Other test may perform clinically indicate . Patients must accessible treatment followup . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . Metastatic disease ( M1 ) Prior systemic anticancer therapy breast cancer ( chemotherapy , hormone therapy immunotherapy ) Prior radiation therapy breast cancer . Preexisting motor sensory neurotoxicity severity &gt; grade 2 NCI criterion . Serious illness medical condition : Congestive heart failure unstable angina pectoris , previous history myocardial infarction within 1 year study entry , uncontrolled hypertension highrisk uncontrolled arrythmias History significant neurological psychiatric disorder would prohibit understanding give informed consent . Active uncontrolled infection Active peptic ulcer , unstable diabetes . Past ( less 5 year ) current history neoplasm except curatively treat basal cell skin cancer situ carcinoma cervix . Concurrent treatment hormonal replacement therapy : treatment stop least 15 day study entry Concurrent treatment experimental drug . No participation another clinical trial investigational market drug within 30 day prior study entry . Concurrent treatment anticancer therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>elderly</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>Caelyx</keyword>
</DOC>